

New Products - Mekinist

Mekinist (**trametinib dimethyl sulfoxide**) is a reversible allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and kinase activity. MEK proteins are critical components of the extracellular signal-related kinase (ERK) pathway. In melanoma and other cancers, this pathway is often activated by mutated forms of BRAF which activates MEK and stimulates tumour cell growth. Trametinib inhibits activation of MEK by BRAF and inhibits MEK kinase activity. Trametinib inhibits growth of BRAF^{V600} mutant melanoma cell lines and demonstrates anti-tumour effects in BRAF^{V600} mutant melanoma animal models. Mekinist in combination with dabrafenib is indicated for the treatment of patients with BRAF^{V600} mutation positive unresectable stage III or metastatic (stage IV) melanoma and as monotherapy is indicated for the treatment of patients with BRAF^{V600} mutation positive unresectable stage III or metastatic (stage IV) melanoma and in whom either there is intolerance to BRAF inhibitors or BRAF inhibitors cannot be used. Mekinist is available as 0.5 mg and 2 mg film coated tablets in packs of 30's.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.